146 related articles for article (PubMed ID: 37302160)
41. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
Saida Y; Watanabe S; Abe T; Shoji S; Nozaki K; Ichikawa K; Kondo R; Koyama K; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Tsukada H; Makino M; Iwashima A; Sato K; Matsumoto N; Yoshizawa H; Kikuchi T
Thorac Cancer; 2019 Nov; 10(11):2106-2116. PubMed ID: 31507098
[TBL] [Abstract][Full Text] [Related]
43. Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors.
Yun PJ; Wang GC; Chen YY; Wu TH; Huang HK; Lee SC; Chang H; Huang TW
PLoS One; 2019; 14(5):e0215923. PubMed ID: 31048854
[TBL] [Abstract][Full Text] [Related]
44. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
[TBL] [Abstract][Full Text] [Related]
45. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
46. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
47. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Chang HC; Wang CC; Tseng CC; Huang KT; Chen YM; Chang YP; Lai CH; Fang WF; Lin MC; Chuang HY
Thorac Cancer; 2023 Nov; 14(32):3208-3216. PubMed ID: 37737541
[TBL] [Abstract][Full Text] [Related]
48. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
Tan WL; Ng QS; Lim C; Tan EH; Toh CK; Ang MK; Kanesvaran R; Jain A; Tan DSW; Lim DW
BMC Cancer; 2018 Dec; 18(1):1198. PubMed ID: 30509246
[TBL] [Abstract][Full Text] [Related]
49. The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan.
Cheng WC; Shen YC; Chien CR; Liao WC; Chen CH; Hsia TC; Tu CY; Chen HJ
Thorac Cancer; 2022 May; 13(10):1505-1512. PubMed ID: 35394114
[TBL] [Abstract][Full Text] [Related]
50. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
51. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
52. Tislelizumab plus chemotherapy for patients with
Zhong H; Zhang X; Tian P; Chu T; Guo Q; Yu X; Yu Z; Li Y; Chen L; Liu J; Zhang Y; Guan Y; Shi X; Wang J; Zhao Y; Han B
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597849
[TBL] [Abstract][Full Text] [Related]
53. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
54. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
[TBL] [Abstract][Full Text] [Related]
55. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
Bouchez C; Pluvy J; Soussi G; Nguenang M; Brosseau S; Tourne M; Collin M; Théou-Anton N; Guyard A; Ammar J; Khalil A; Zalcman G; Gounant V
BMC Cancer; 2020 Dec; 20(1):1186. PubMed ID: 33272243
[TBL] [Abstract][Full Text] [Related]
57. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
58. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
Gui Q; Liu J; Li D; Xu C
World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
60. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
Chamorro DF; Cardona AF; Rodríguez J; Ruiz-Patiño A; Arrieta O; Moreno-Pérez DA; Rojas L; Zatarain-Barrón ZL; Ardila DV; Viola L; Recondo G; Blaquier JB; Martín C; Raez L; Samtani S; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Archila P; Bermudez M; Gamez T; Russo A; Malapelle U; de Miguel Perez D; de Lima VCC; Freitas H; Saldahna E; Rolfo C; Rosell R;
Target Oncol; 2023 May; 18(3):425-440. PubMed ID: 37017806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
